Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Venetoclax for elderly ALL?

Daniel DeAngelo • 10 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia Venetoclax

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, covers the investigation of venetoclax for acute lymphoblastic leukemia (ALL). He discusses the phase 1 multicenter study of venetoclax with mini-hyper-CVD in older adults with untreated or relapsed/refractory B-ALL and T-ALL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Daniel DeAngelo

1:36
IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDCN
Daniel DeAngelo • 3 Dec 2020
1:36
Diagnostic pathology is crucial to guide treatment options
Daniel DeAngelo • 3 Dec 2020
2:29
ASH 2020: Treatment advances in mastocytosis
Daniel DeAngelo • 3 Dec 2020
3:57
Major ALL treatment updates at ASH 2020
Daniel DeAngelo • 3 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals